Latest Regenerative Medicine News

Page 1 of 9
Cynata Therapeutics has completed its $912,962 entitlement offer and secured firm commitments for a further $550,000 placement. The second raise still requires shareholder approval and will bring additional shares and options into an already heavily funded capital structure.
Ada Torres
Ada Torres
4 Nov 2026
Marine Biomedical has secured US FDA 510(k) clearance for PearlBone, giving Orthocell a clearer path into bone regeneration through its 12% strategic stake and distribution rights. The commercial opportunity is advancing, but revenue, launch timing and definitive distribution arrangements remain undisclosed.
Ada Torres
Ada Torres
3 Nov 2026
Orthocell has recorded its strongest month of US Remplir sales since launch, with 92 units generating A$279,000 in October. The result points to improving surgeon adoption and hospital access, although one month of sales does not yet establish a durable run rate or profitability.
Victor Sage
Victor Sage
2 Nov 2026
Osteopore reported record quarterly revenue of A$859,000 in Q3 CY26 as it added market access in Thailand and Saudi Arabia and completed its first customised Hainan implant. The regenerative implant maker remains cash-flow negative, with A$712,000 in cash and A$14 million still available under its convertible note facility.
Victor Sage
Victor Sage
30 Oct 2026
Mesoblast has posted a 44% rise in first-quarter Ryoncil revenue to US$28 million while sharply reducing operating cash use. The biotechnology company also completed treatment in its 350-patient chronic low back pain trial and received FDA confirmation that a heart-failure BLA filing may proceed.
Ada Torres
Ada Torres
29 Oct 2026
Orthocell’s flagship Remplir nerve-repair product gained ground in the US and Thailand during the September quarter, even as total revenue slipped from the June period. The company reported A$39 million in available funds and said it does not currently expect to raise additional capital.
Ada Torres
Ada Torres
22 Oct 2026
Orthocell says Remplir was placed successfully in five complex robotic prostatectomy cases, with no device-related complications reported over approximately 12 months. The preliminary results will guide a larger prospective trial ahead of a planned US expansion for the nerve repair product.
Ada Torres
Ada Torres
13 Oct 2026
Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.
Ada Torres
Ada Torres
21 Sept 2026
Vitrafy Life Sciences has secured its first US cell and gene therapy foothold by deploying its cryopreservation technology at Charter Medical's Innovation Hub, signalling a strategic expansion into a high-value biopharma segment.
Ada Torres
Ada Torres
2 Sept 2026
Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.
Ada Torres
Ada Torres
31 Aug 2026
Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.
Ada Torres
Ada Torres
17 Aug 2026
Osteopore has inked a three-year distribution agreement with Al-Umnia Medical to bring its 3D-printed orthopaedic implants to five Gulf countries, targeting a rapidly expanding regional market.
Ada Torres
Ada Torres
6 Aug 2026

Browse the archive

Full archive